Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

B8299

Sigma-Aldrich

N-Butyldeoxynojirimycin

film (dried in situ), ≥98% (TLC)

Synonym(s):

Miglustat, NB-DNJ

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H21NO4
CAS Number:
72599-27-0
Molecular Weight:
219.28
MDL number:
MFCD00272581
UNSPSC Code:
12352200
PubChem Substance ID:
24892070
NACRES:
NA.32

product name

N-Butyldeoxynojirimycin, film (dried in situ)

Assay

≥98% (TLC)

Quality Level

200

form

film (dried in situ)

solubility

water: 9.80-10.20 mg/mL, clear, colorless

storage temp.

2-8°C

SMILES string

CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO

InChI

1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1

InChI key

UQRORFVVSGFNRO-UTINFBMNSA-N

Gene Information

human ... UGCG(7357)

Related Categories

General description

N-Butyldeoxynojirimycin is an alkylated product of imino sugar deoxynojirimycin.

Application

N-Butyldeoxynojirimycin has been used:
  • in the inhibition of glycolipid synthesis in neuroblastoma cells
  • in the inhibition the ceramide-specific glycosyltransferase in hepatocytes
  • in the inhibition of β-glucosidase (GBA2) using fluorescence- activity assay in human embryonic kidney (HEK293) cells.

Biochem/physiol Actions

N-Butyldeoxynojirimycin is an inhibitor of glucosyltransferase and α-glucosidases. N-Butyldeoxynojirimycin, also known as misglustat, reduces glycolipid levels by substrate reduction therapy (SRT) and is effectively used for the treatment of glycosphingolipid lysosomal storage disorder, Gaucher disease.
α-glucosidase Inhibitor

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Beom Hee Lee et al.
Medicine, 96(45), e8492-e8492 (2017-11-16)
Gaucher disease (GD) is caused by a deficiency in the lysosomal enzyme glucocerebrosidase. Enzyme replacement therapy (ERT) is recommended for clinical improvement. The efficacy and safety of a new imiglucerase, Abcertin, were assessed in 7 Egyptian patients with treatment-naïve type
Frances M Platt et al.
Nature reviews. Disease primers, 4(1), 27-27 (2018-10-03)
Lysosomal storage diseases (LSDs) are a group of over 70 diseases that are characterized by lysosomal dysfunction, most of which are inherited as autosomal recessive traits. These disorders are individually rare but collectively affect 1 in 5,000 live births. LSDs
Arunabha Ghosh et al.
Orphanet journal of rare diseases, 12(1), 117-117 (2017-06-28)
Mucopolysaccharidosis type III is a progressive, neurodegenerative lysosomal storage disorder for which there is currently no effective therapy. Though numerous potential therapies are in development, there are several challenges to conducting clinical research in this area. We seek to make
Cytoskeletal inhibitors, anti-adhesion molecule antibodies, and lectins inhibit hepatocyte spheroid formation
Nakamura M, et al.
Acta Medica Okayama, 56(1), 43-50 (2002)
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement
Cox TM, et al.
Journal of inherited metabolic disease, 26(6), 513-526 (2003)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service